Stockscreener 앱 받기
0.6638
1.07%
-0.0072
전일 마감가:
$0.671
열려 있는:
$0.677
하루 거래량:
1.17M
Relative Volume:
0.48
시가총액:
$26.22M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-0.4945
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
+0.56%
1개월 성능:
-84.78%
6개월 성능:
-73.13%
1년 성능:
-77.27%
1일 변동 폭
$0.6627
$0.6901
1주일 범위
$0.6602
$0.74
52주 변동 폭
$0.6311
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6638 | 26.50M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-12-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionVTGN - TMX Newsfile
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit - PR Newswire
2026-01-18 | VTGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
Faruqi & Faruqi Investigates Vistagen Investors' Claims Ahead of March 2026 Deadline - Intellectia AI
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Short Interest in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Rises By 88.9% - Defense World
Vistagen Therapeutics (VTGN) Faces Class Action Over Misleading Trial Results, Stock Plummets 80% - Intellectia AI
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc. - PR Newswire
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Vistagen Therapeutics Faces Class Action Lawsuit, Shareholders May Claim Compensation - Intellectia AI
Vistagen Therapeutics Faces Class Action Lawsuit for Misleading Investors on Drug Development - Intellectia AI
VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire Inc.
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT - GlobeNewswire
About Us - FinancialContent
Vistagen Therapeutics Faces Class Action for Securities Fraud, Investors Can Claim Losses - Intellectia AI
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The AI Journal
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Vistagen Drug Trial Collapse Triggers Investor Lawsuit Wave - TipRanks
Vistagen Therapeutics (VTGN) Accused of Misleading Investors, Stock Plummets 80% - Intellectia AI
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action - Weekly Voice
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives $0.95 Consensus PT from Analysts - Defense World
Vistagen Therapeutics (VTGN) price target decreased by 50.00% to 7.40 - MSN
Vistagen Therapeutics, Inc. Unveils New Corporate Presentation - TradingView — Track All Markets
Vistagen fails in late-stage trial for social anxiety disorder therapy - MSN
Should I hold or sell Vistagen Therapeutics Inc. stock in 2025Insider Buying & Fast Exit Strategy with Risk Control - Улправда
VTGN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vistagen Therapeutics, Inc. investment - ACCESS Newswire
Vistagen appoints Nick Tressler as CFO - MSN
Lost Money on Vistagen Therapeutics, Inc.(VTGN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
VistaGen’s PALISADE-3 trial fails primary endpoint in SAD - MSN
Aug Volume: Should I hold or sell Vistagen Therapeutics Inc stock in 2025July 2025 Intraday Action & Stepwise Trade Execution Plans - moha.gov.vn
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Increase in Short Interest - Defense World
Vistagen Therapeutics Inc (VTGN) deserves deeper analysis - uspostnews.com
ATTENTION VTGN SHAREHOLDERS: Investors who Lost Money on Vistagen Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation - ACCESS Newswire
Lost Money on Vistagen Therapeutics, Inc.(VTGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
VTGN STOCK ALERT: Levi & Korsinsky Notifies Vistagen Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
William Blair downgrades Vistagen Therapeutics (VTGN) - MSN
Finance Watch: Vistagen To Cut Costs After Phase III Trial Failure - Citeline News & Insights
Levi & Korsinsky Announces an Investigation on Behalf of Vistagen Therapeutics, Inc. (VTGN) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint - Investing.com Nigeria
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint By Investing.com - Investing.com South Africa
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD - TipRanks
Vistagen Therapeutics Reports Phase 3 Study Results - TradingView — Track All Markets
Vistagen Therapeutics, Inc. (VTGN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Is Vistagen Therapeutics Stock Built to Withstand More Downside? - Trefis
How Vistagen Therapeutics Inc. stock reacts to bond yieldsWeekly Trade Analysis & Daily Growth Stock Investment Tips - Улправда
Can Vistagen Therapeutics Inc. stock sustain institutional interestJuly 2025 Selloffs & Reliable Momentum Entry Alerts - Улправда
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):